China-based 3SBio Inc. (HKG: 1530) announced last week a strategic partnership with US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO). The collaboration will focus on the cell and gene therapy (CGT) field, leveraging 3SBio’s internationally certified R&D and manufacturing platforms alongside Thermo Fisher’s Gibco CTS franchise.
Strategic Collaboration
This partnership combines 3SBio’s strengths in R&D and manufacturing with Thermo Fisher’s extensive expertise and Gibco CTS franchise. Together, the companies aim to drive innovation and development in the rapidly growing CGT sector.
Financial Details
No financial details of the partnership were disclosed.-Fineline Info & Tech
